- Home
- NMS vs ANL Comparison
NMS vs ANL Comparison
Compare NMS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- ANL
- Stock Information
- Founded
- NMS 1993
- ANL 2004
- Country
- NMS United States
- ANL Cayman Islands
- Employees
- NMS N/A
- ANL N/A
- Industry
- NMS Finance Companies
- ANL
- Sector
- NMS Finance
- ANL
- Exchange
- NMS Nasdaq
- ANL Nasdaq
- Market Cap
- NMS 71.2M
- ANL 61.8M
- IPO Year
- NMS N/A
- ANL 2023
- Fundamental
- Price
- NMS $11.82
- ANL $1.51
- Analyst Decision
- NMS
- ANL Hold
- Analyst Count
- NMS 0
- ANL 1
- Target Price
- NMS N/A
- ANL N/A
- AVG Volume (30 Days)
- NMS 12.0K
- ANL 6.5K
- Earning Date
- NMS 01-01-0001
- ANL 11-11-2025
- Dividend Yield
- NMS 4.11%
- ANL N/A
- EPS Growth
- NMS N/A
- ANL N/A
- EPS
- NMS N/A
- ANL N/A
- Revenue
- NMS N/A
- ANL N/A
- Revenue This Year
- NMS N/A
- ANL N/A
- Revenue Next Year
- NMS N/A
- ANL N/A
- P/E Ratio
- NMS N/A
- ANL N/A
- Revenue Growth
- NMS N/A
- ANL N/A
- 52 Week Low
- NMS $9.21
- ANL $1.10
- 52 Week High
- NMS $12.18
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- NMS 47.33
- ANL 34.86
- Support Level
- NMS $11.73
- ANL $1.55
- Resistance Level
- NMS $11.85
- ANL $1.67
- Average True Range (ATR)
- NMS 0.15
- ANL 0.09
- MACD
- NMS -0.02
- ANL -0.02
- Stochastic Oscillator
- NMS 35.48
- ANL 12.00
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.